San Francisco, CA. December 14, 2022 — Vial, a global tech-enabled CRO providing next-generation clinical trial management services, welcomes Dr. Peter Goadsby as a new Central Nervous System (CNS) advisory board member to their Neurology CRO. Dr. Goadsby is the Director of the NIHR Wellcome Trust at the King’s College Clinical Research Facility, London, and a Professor of Neurology at the University of California, San Francisco.
Dr. Goadsby is a world-renowned headache medicine specialist whose clinical research focuses on understanding the pathophysiology of and guiding the treatment of migraine and cluster headaches. His research has provided a deeper understanding of the cause of migraine headaches and has significantly impacted the neurology field by influencing the current standard of treatment for cluster headaches.
Dr. Goadsby’s neuroscience research has been widely recognized and awarded. In 2021, he and three of his colleagues received the prestigious Brain Prize, the world’s largest brain research prize, from the Lundbeck Foundation for their work on the involvement of CGRP in migraine development. He also holds a patent for magnetic stimulation for headaches.
“I am grateful to the patients and their families that come to these trials looking for relief. Their time is invaluable. My mission is to discover successful treatments that can provide the relief needed without all the delays that can come with clinical trials. Vial aims to empower researchers with advanced technological tools that can help treatments get to patients sooner, which is a mission I can support,” said Dr. Goadsby on joining Vial’s Scientific Advisory Board.
Dr. Goadsby will act as a founding scientific advisor to Vial’s Neurology CRO to support neurology sponsors’ and patients’ greatest needs.
The Vial Neurology CRO distinguishes itself by leveraging digital technology, such as its Vial Technology Platform, which brings together eSource, EDC, and ePRO, in one connected system to streamline site processes. These best-in-class CRO services will accelerate the development of new therapies and devices for neurology and CNS sponsors and patients.
“Dr. Goadsby has led an extraordinary career in neurology, and we are honored to have his expertise on our advisory board,” said Simon Burns, Co-Founder and CEO of Vial.
In addition to Vial’s Neurology CRO Advisory Board, Dr. Goadsby serves on the scientific board and executive committee for the American Registry Migraine Research, is a Trustee for The Migraine Trust, and is the Chairman of the Organisation for the Understanding of Cluster Headache – OUCH (UK). He is also on the board of directors for the American Headache Society and American Migraine Foundation.
About Vial: Vial is a tech-enabled, next-generation CRO that promises faster and higher-quality execution of trials for less cost. The Vial Contract Research Organization (CRO) delivers on the promise of more efficient trials through its innovative technology platform that powers trials end-to-end from site startup to database lock. Vial’s technology platform combines modern, intuitive eSource, EDC, and ePRO into one connected system, streamlining site processes and enabling considerable efficiencies. Vial operates across multiple Therapeutic Areas (Dermatology CRO, Ophthalmology CRO, Oncology CRO, Gastroenterology CRO, Neurology CRO, and Cardiology CRO). Vial is a San Francisco, California-based company with over 125 employees.